Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Drug Combinations
Female
Fluorouracil
/ therapeutic use
Glucuronosyltransferase
/ genetics
Heterozygote
Humans
Irinotecan
/ pharmacology
Leucovorin
/ therapeutic use
Male
Middle Aged
Organometallic Compounds
/ therapeutic use
Oxaliplatin
Pancreatic Neoplasms
/ drug therapy
Polymorphism, Genetic
/ genetics
FOLFIRINOX
UGT1A1
chemotherapy
pancreatic cancer
toxicity
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
15
08
2018
revised:
13
11
2018
accepted:
14
11
2018
pubmed:
18
11
2018
medline:
12
2
2019
entrez:
18
11
2018
Statut:
ppublish
Résumé
Studies have indicated an association between UDP-glucuronosyltransferase-1A1 (UGT1A1) genetic polymorphisms and irinotecan-induced toxicity. We undertook this study to investigate the association between UGT1A1 genetic polymorphisms and toxicity in patients treated with the FOLFIRINOX (comprising oxaliplatin, irinotecan, fluorouracil, and leucovorin) chemotherapy regimen in the JASPAC 06 study. Patients screened for UGT1A1*6 and UGT1A1*28, and treated with either the original FOLFIRINOX (oxaliplatin 85 mg/m
Identifiants
pubmed: 30447099
doi: 10.1111/cas.13883
pmc: PMC6361560
doi:
Substances chimiques
Drug Combinations
0
Organometallic Compounds
0
folfirinox
0
Oxaliplatin
04ZR38536J
Irinotecan
7673326042
UGT1A1 enzyme
EC 2.4.1.-
Glucuronosyltransferase
EC 2.4.1.17
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
707-716Subventions
Organisme : Chugai Pharmaceutical
Organisme : Eizai
Organisme : Kyowa-Hakko Kirin, Co., Ltd.
Organisme : Zeria Pharmaceutical
Organisme : Taiho Pharmaceutical Co. Ltd.
Organisme : Merck Serono
Organisme : AstraZeneca
Organisme : NanoCarrier
Organisme : MSD
Organisme : Yakult Honsha Co., Ltd
Organisme : Daiichi Sankyo Co., Ltd
Organisme : Shizuoka Industrial Foundation Pharma Valley Center
Informations de copyright
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Drug Des Devel Ther. 2015 Jul 17;9:3677-83
pubmed: 26229432
J Clin Invest. 1998 Feb 15;101(4):847-54
pubmed: 9466980
Oncology. 2009;76(5):315-21
pubmed: 19299905
Br J Cancer. 2016 Mar 29;114(7):737-43
pubmed: 27022826
Med Oncol. 2013;30(3):604
pubmed: 23686699
Clin Cancer Res. 2010 Aug 1;16(15):3832-42
pubmed: 20562211
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4
pubmed: 9653159
Clin Pharmacol Ther. 2004 Jun;75(6):501-15
pubmed: 15179405
Br J Cancer. 2015 May 12;112(10):1709-16
pubmed: 25880011
Pharmacogenetics. 1999 Oct;9(5):591-9
pubmed: 10591539
Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60
pubmed: 24448639
Pharmacogenet Genomics. 2005 Oct;15(10):677-85
pubmed: 16141793
Pancreas. 2018 May/Jun;47(5):631-636
pubmed: 29683973
Cancer Sci. 2014 Oct;105(10):1321-6
pubmed: 25117729
J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5
pubmed: 17728214
N Engl J Med. 1995 Nov 2;333(18):1171-5
pubmed: 7565971
Cancer Sci. 2011 Oct;102(10):1868-73
pubmed: 21740478
Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023
pubmed: 29633005
Int J Clin Oncol. 2009 Apr;14(2):136-42
pubmed: 19390945
Biochem Mol Biol Int. 1998 Sep;46(1):21-6
pubmed: 9784835
Cancer Res. 2000 Dec 15;60(24):6921-6
pubmed: 11156391
Med Oncol. 2013;30(3):630
pubmed: 23783485
Bioconjug Chem. 2001 Nov-Dec;12(6):1074-80
pubmed: 11716702
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer Sci. 2019 Feb;110(2):707-716
pubmed: 30447099
Clin Cancer Res. 2002 Aug;8(8):2605-11
pubmed: 12171891
Cancer Sci. 2007 Sep;98(9):1461-7
pubmed: 17627617
Pharmacogenomics J. 2014 Apr;14(2):120-9
pubmed: 23529007